Company intelligence / Profile preview
Aprea Therapeutics
Doylestown, Pennsylvania, United Statesaprea.com ↗
- Ownership
- Public · APRE
- Development stage
- Other
01
Overview
Currently conducting Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051 with preliminary results showing good tolerability. Also advancing Phase 1/2a ABOYA-119 study for ATRN-119, a macrocyclic ATR inhibitor, with twice-daily dosing regimen implemented to optimize clinical outcomes[9][6].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesMacrocyclic inhibitors
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Financials
- Market cap
- $6.2M
- Total revenue
- $0
- Enterprise value
- $-31.6M
Beyond the preview
Go deeper on Aprea Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aprea Therapeutics.